Key result
MCP-1 release is higher in visceral than subcutaneous adipose tissue (P<0.01) and in obese subjects (P<0.05), but these differences disappear after adjusting for tissue-resident macrophages.
Why the study?
Does exposure to antidiabetic drugs like metformin and thiazolidinediones reduce MCP-1 release in human adipose tissue cultures?
Does exposure to antidiabetic drugs like metformin and thiazolidinediones reduce MCP-1 release in human adipose tissue cultures?
p-value: p=<0.01
MCP-1 release in adipose tissue correlates with resident macrophage numbers and is reduced by metformin and thiazolidinediones, suggesting these antidiabetic drugs have anti-inflammatory properties.
Should not change practice; leaves open whether adipose macrophages drive MCP-1-mediated atherosclerosis.
UNLABELLED: Human adipose tissue (AT) produces several adipokines including monocyte chemoattractant protein (MCP)-1, involved in the pathogenesis of atherosclerosis. OBJECTIVE: Human AT cultures, isolated adipocytes, and stromal-vascular cells were used to investigate the relationship among AT-resident macrophages, MCP-1, and adiposity and the regulation of MCP-1. RESULTS: mRNA levels of specific macrophage markers (CD68 and CD14) are correlated with adiposity in sc AT and visceral AT (P < 0.05). MCP-1 production is higher in stromal-vascular cells vs. adipocytes (P < 0.01) and correlates with macrophage markers in both AT compartments (P < 0.05). MCP-1 release is higher in obese subjects (P < 0.05) and in VAT (P < 0.01), but after adjusting for AT-resident macrophages, the differences disappear. MCP-1 is stimulated by IL-1beta, TNF-alpha, IL-8, IL-4, and IL-6 + IL-6-soluble receptor and is decreased by dexamethasone, IL-10, metformin, and thiazolidinediones. DISCUSSION: MCP-1 is correlated with specific macrophage markers, adiposity, and AT localization, but the relationship seems to be related to the number of AT-resident macrophages. Despite this, MCP-1 may be involved in obesity-related health complications, and the decrease of MCP-1 by metformin and thiazolidinediones suggests that these antidiabetic compounds have antiinflammatory properties improving the low-grade inflammatory state observed in obesity.
No takes yet. Share an insight, caveat, or question.
Bruun et al. (2005) studied Obesity. Visceral adipose tissue and obesity vs. Subcutaneous adipose tissue and non-obese subjects was evaluated on MCP-1 release (p=<0.01). MCP-1 release is higher in visceral than subcutaneous adipose tissue (P<0.01) and in obese subjects (P<0.05), but these differences disappear after adjusting for tissue-resident macrophages.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: